Fewer Drug Launches In 2022, But Standouts Among Them

Lilly's Mounjaro and Roche's Vabysmo appear on track to be fast blockbusters in a year that saw the fewest drug launches since 2016.

speedboat
A few new drugs got off to a fast start in 2022 • Source: Shutterstock

Fewer new drugs launched in the US in 2022 than in recent years, but the year's new launches included some stellar commercial performers, such as Pfizer Inc.'s Paxlovid (nirmarelvir/ritonavir), Roche Holding AG's Vabysmo (faricimab) and Eli Lilly and Company's Mounjaro (tirzepatide). The year's class also included some promising scientific advances including three new gene therapies and a new drug in the notoriously challenging area of amyotrophic lateral sclerosis (ALS), Amylyx Pharmaceuticals, Inc.'s Relyvrio (sodium phenylbutyrate/taurusodiol).

Around 40 new drugs launched in the US in 2022, the lowest number since 2016. ([A#3SC098446]) Not all of the...

More from New Products

J&J Seeks Schizophrenia Relapse Indication For Caplyta

 

The company is expecting US FDA approval of the drug in a bigger indication, major depressive disorder, later this year.

Novartis Secures Approval For First Malaria Therapy for Babies

 
• By 

Coartem Baby to be rolled out in eight African countries in the autumn.

Pipeline Watch: Ten Approvals And Eleven Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

2025’s Biggest Launches – Half-Year Progress Report

 

Trial setbacks and extra regulatory scrutiny have hit the progress of some new drugs towards expected approvals this year, but early successes have boosted the commercial prospects of others. Fears of disruption from changes at the US FDA are so far unfounded.

More from Scrip